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1. Introduction
Prepulse inhibition (PPI) of acoustic startle response is a para-
digm commonly used to assess sensorimotor gating, a preatten-
tive ability which is impaired in patients with schizophrenia and 
in animals acutely treated with dopamine agonists and NMDA 
antagonists. This paradigm is thought to possess face, construct, 
and predictive validity for the information processing deficits ob-
served in patients with schizophrenia (Geyer et al., 1990; Swerd-
low et al., 1994). Besides its popularity in the field of animal mod-
els of schizophrenia, it has also been successfully used to screen 
chemical compounds with potential antipsychotic activity (Geyer 
et al., 2001; Swerdlow et al., 1991), to rank order clinical potency of 
approved antipsychotics (Swerdlow et al., 2008), and to differen-
tiate atypical from typical antipsychotics (Geyer and Ellenbroek, 
2003). For example, antagonism of acute apomorphine-induced 
disruption of PPI is shown to be a reliable and sensitive screen-
ing test for antipsychotic activity (Rigdon and Viik, 1991; Swerdlow 
and Geyer, 1993), and acute NMDA antagonists PPI models are 
found to be effective in differentiating atypical from typical anti-
psychotics to some extent (Geyer and Ellenbroek, 2003).
One of the lingering issues associated with many antipsy-
chotic PPI studies is the clinical relevance of acute effect of an-
tipsychotic treatment on deficient PPIs. Because antipsychotic 
treatments in patients with schizophrenia are administered re-
peatedly and chronically, the extent to which the acute effect of 
antipsychotic treatment in various PPI models reflects the clin-
ically relevant action against psychosis or cognitive deficits re-
mains unclear. In recent years, several clinical reports suggest 
that antipsychotic action starts early and increases in magnitude 
with repeated treatment (Agid et al., 2003, 2006; Emsley et al., 
2006; Glick et al., 2006; Kapur et al., 2005; Leucht et al., 2005; 
Raedler et al., 2007). An animal model based on the PPI para-
digm that faithfully captures this time course of action is still 
lacking. Previous work on the effects of repeated antipsychotic 
treatment on deficient PPIs is rather limited. Some have exam-
ined the treatment effects after a certain period of treatment 
has elapsed (e.g., ~21 days after the first drug administration), 
instead of during the chronic treatment period (Andersen and 
Pouzet, 2001; Feifel and Priebe, 1999; Rueter et al., 2004). Others 
have examined the drug effect only at the beginning and end of 
treatment period (Briody et al., 2010; Feifel et al., 2007), and are 
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Abstract
Antagonism of prepulse inhibition (PPI) deficits produced by psychotomimetic drugs has been widely used as an effec-
tive tool for the study of the mechanisms of antipsychotic action and identifying potential antipsychotic drugs. Many 
studies have relied on the acute effect of a single administration of antipsychotics, whereas patients with schizophrenia 
are treated chronically with antipsychotic drugs. The clinical relevance of acute antipsychotic effect in this model is still 
an open question. In this study, we investigated the time course of repeated antipsychotic treatment on persistent PPI 
deficit induced by repeated phencyclidine (PCP) treatment. After a baseline test with saline, male Sprague–Dawley rats 
were repeatedly injected with either vehicle, haloperidol (0.05 mg/kg), clozapine (5.0 or 10.0 mg/kg), olanzapine (2.0 mg/
kg), risperidone (1.0 mg/kg) or quetiapine (10 mg/kg), followed by PCP (1.5 mg/kg, sc) and tested for PPI once daily for 
6 consecutive days. A single injection of PCP disrupted PPI and this effect was maintained with repeated PCP injections 
throughout the testing period. Acute clozapine, but not other antipsychotic drugs, attenuated acute PCP-induced PPI dis-
ruption at both tested doses. With repeated treatment, clozapine and quetiapine maintained their attenuation, while ris-
peridone enhanced its effect with a significant reduction of PCP-induced disruption toward the end of treatment period. 
In contrast, repeated haloperidol and olanzapine treatments were ineffective. The PPI effects of these drugs were more 
conspicuous at a higher prepulse level (e.g. 82 dB) and were dissociable from their effects on startle response and general 
activity. Overall, the repeated PCP–PPI model appears to be a useful model for the study of the time-dependent antipsy-
chotic effect, and may help identify potential treatments that have a quicker onset of action than current antipsychotics.
Keywords: prepulse inhibition of acoustic startle, repeated phencyclidine treatment, Haloperidol, Clozapine, Olanzap-
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thus limited in the ability to track changes that have occurred 
during the treatment period. To the best of our knowledge, only 
two studies have examined the effect of repeated antipsychotic 
treatment on deficient PPIs during the drug treatment period 
with positive results (Martinez et al., 2000; Pietraszek and Os-
sowska, 1998). They both reported that chronic administra-
tions of haloperidol reversed the disruptive effect of PCP on PPI. 
What is less known is whether repeated administrations of atyp-
ical antipsychotics (e.g. clozapine, olanzapine) also exhibit this 
effect. Because acute treatment of clozapine (Bakshi et al., 1994), 
olanzapine (Bakshi and Geyer, 1995) or quetiapine (Swerdlow et 
al., 1996) is immediately effective in reversing or reducing PCP-
induced PPI disruption, it would be important to determine how 
repeated treatment of these drugs would influence PCP-induced 
PPI disruption. If the reversal effect is maintained or even in-
creased over the treatment period, it would suggest that the PCP 
PPI model based on repeated antipsychotic treatment regimens 
may be a valid model to capture the time course of clinically rel-
evant effects of antipsychotic treatment. This model may, in 
turn, be used to study the underlying neurobiological mecha-
nisms and identify potential treatments that may have quicker 
onset of action than the currently used antipsychotics.
In the present study, we investigated how repeated adminis-
trations of haloperidol, clozapine, risperidone, olanzapine and 
quetiapine affect PCP-induced PPI disruption. Haloperidol pri-
marily binds to DA D2 receptors, whereas other atypical anti-
psychotics are high 5-HT2A and low D2 antagonists. Clozap-
ine has high affinities for serotonin 5-HT2A, muscarinic M1 and 
histamine H1 receptors, moderate affinities for D4, 5-HT2c, α1-
adrenergic receptors, and a relatively low affinity for D2. Olan-
zapine has high affinities for 5-HT2A, M1 and H1 receptors and 
moderate affinities for D1, D2, D4 and α1 receptors. Risperidone 
demonstrates high affinities for D2, 5-HT2A and α1-adrenergic re-
ceptors, as well as some affinities for D1, D4, α1-adrenergic, and 
α2-adrenergic receptors. Quetiapine, very much like clozapine, 
also has high to moderate affinities for α1-adrenergic, 5-HT2A, 
H1 and low affinities for D1, D2 and α2-adrenergic receptors (Jib-
son and Tandon, 1998; Miyamoto et al., 2005). We were partic-
ularly interested in whether repeated antipsychotic treatment 
would produce a progressively increased attenuation of PCP-in-
duced PPI deficits. In our previous work, we have demonstrated 
that repeated antipsychotic treatment in the conditioned avoid-
ance response model and PCP-induced hyperlocomotion model 
is capable of modeling the time course of antipsychotic effect 
(Li et al., 2007, 2010; Mead and Li, 2010; Sun et al., 2009). Re-
peated antipsychotic treatment progressively enhances its dis-
ruption of avoidance responding and progressively potentiates 
its inhibition of PCP-induced hyperlocomotion across the drug 
testing sessions. Because all three models are commonly used to 
screen antipsychotic activity with high predictive validity, it is of 
great importance to determine whether PCP-induced PPI defi-
cit model based on repeated antipsychotic treatment regimen 
would also capture the time course of antipsychotic treatment in 
the clinic as shown in the other two models.
2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats (250–275 g upon arrival, 
Charles River, Portage, MI) were housed two per cage, in 
48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages 
under 12-h light/dark conditions (light on between 6:00 am and 
6:00 pm). Room temperature was maintained at 22 ± 1° with a 
relative humidity of 55–60%. Food and water was available ad li-
bitum. Animals were allowed at least one week of habituation to 
the animal facility before being used in experiments. All proce-
dures were approved by the animal care committee at the Uni-
versity of Nebraska-Lincoln.
2.2. Prepulse inhibition of acoustic startle reflex apparatus
The prepulse inhibition test was performed using six Startle 
Monitor Systems (Kinder Scientific, Julian, CA). Each system, 
controlled by a PC, was housed in a compact sound attenua-
tion cabinet (35.56 cm wide × 27.62 cm deep × 49.53 cm high). A 
speaker (diameter: 11 cm) mounted on the cabinet’s ceiling was 
used to generate acoustic stimuli (70 dB–120 dB white noise). The 
startle response was measured by a piezoelectric sensing plat-
form on the floor, which was calibrated daily. During testing, rats 
were placed in a rectangular box made of transparent Plexiglas 
(19 cm wide × 9.8 cm deep × 14.6 high) with an adjustable ceiling 
positioned atop the box, providing only limited restraint while 
prohibiting ambulation.
2.3. Drugs
The injection solution of phencyclidine hydrochloride (gift from 
NIDA Chemical Synthesis and Drug Supply Program) was ob-
tained by mixing drugs with 0.9% saline. The injection solution 
of haloperidol (5.0 mg/ml ampoules, Shanghai Xudong Haipu 
Pharmaceutical Co., Ltd, Shanghai, China) was obtained by mix-
ing the stock with sterile water. Clozapine, olanzapine, risperi-
done and quetiapine (gifts from the NIMH drug supply pro-
gram) were dissolved in 1.0–1.5% glacial acetic acid in distilled 
water. All injections were administered subcutaneously at a vol-
ume of 1 ml/kg. The dose for each antipsychotic drug was care-
fully chosen based on the following considerations: (1) at the 
chosen doses, all antipsychotic drugs produce a reliable and 
comparable level of disruption of avoidance responding which is 
considered a well-validated animal model for antipsychotic ac-
tivity (Li et al., 2004, 2009a, 2009b; Mead and Li, 2010); (2) all 
antipsychotic drugs give rise to clinical levels of striatal D2 oc-
cupancy (50–80%) at these doses in rats (Kapur et al., 2003); (3) 
these doses have been thoroughly tested in many PPI studies and 
show acute efficacy against either PCP or amphetamine-induced 
PPI disruption (Bakshi and Geyer, 1995; Bakshi et al., 1994; Geyer 
et al., 2001; Martinez et al., 2000; Swerdlow et al., 1996, 2008). 
This dose selection also enabled us to evaluate different drugs on 
a common ground. The PCP at this dose range is shown to in-
duce a robust PPI disruption acutely (Bakshi and Geyer, 1995) 
and as well as chronically (Martinez et al., 2000).
2.3.1. Experiment 1: Effects of repeated haloperidol (0.05 mg/
kg, sc) and clozapine (10 mg/kg, sc) treatment on repeated PCP 
(1.5 mg/kg, sc)-induced PPI disruption
Rats (n = 48) were first handled individually for two days for ap-
proximately 2 min each day to minimize stress during behavioral 
testing. On the first handling day, the rats were acclimated to the 
prepulse inhibition apparatus for 10 min. On the second handling 
day, the rats were habituated to the PPI test procedure, which was 
adapted from Culm and Hammer (2004). The PPI session lasted 
approximately 18 min and began with a 5 minute period of 70 dB 
background noise (which continued throughout the duration of 
the session) followed by four different trial types: PULSE ALONE 
trials and three types of PREPULSE + PULSE trials, which con-
sisted of a 20 ms 73, 76, or 82 dB prepulse (3, 6, and 12 dB above 
background) followed 100 ms later by a 120 dB pulse. Each session 
was divided into 4 blocks. Blocks 1 and 4 were identical, each con-
sisting of 4 PULSE ALONE trials. Blocks 2 and 3 were also iden-
tical and each consisted of 8 PULSE ALONE trials and 5 of each 
PREPULSE + PULSE trial type. A total of 54 trials were presented 
during each test session. Trials within each block were presented 
in a pseudorandom order and were separated by a variable inter-
trial interval averaging 15 s (ranging from 9 to 21 s). Startle magni-
tude was defined as the maximum force (measured in Newtons) 
applied by the rat to the startle apparatus recorded over a period 
of 100 ms beginning at the onset of the pulse stimulus. Between 
each stimulus trial, 100 ms of activity was recorded when no stim-
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ulus was present. These trials were called NOSTIM trials and were 
not included in the calculation of intertrial intervals. Responses 
recorded during NOSTIM trials are considered a measure of gross 
motor activity within the PPI boxes. Startle responses from testing 
blocks 2 and 3 were used to calculate percent prepulse inhibition 
(%PPI) for each acoustic prepulse trial type:
%PPI = 100 – [(average startle response to PREPULSE + PULSE trials ) × 100]                              average startle response to PULSE ALONE trials
One day after the second habituation day, rats were injected 
subcutaneously with saline and tested for PPI 10 min after in-
jection. The averaged %PPI at three prepulse levels (73, 76 and 
82 dB) on this day was used to create matched groups such that 
all groups had comparable baseline PPI performance prior to the 
drug tests. Four groups (n = 12/group) were formed: VEH (ster-
ile water, sc) + VEH (saline, sc), VEH + PCP, HAL + PCP, and 
CLZ + PCP and they were subjected to drug testing for 6 consec-
utive days. During each daily test, rats were first injected with ei-
ther sterile water, HAL (0.05 mg/kg, sc) or CLZ (10.0 mg/kg, sc), 
followed by an injection of saline or PCP (1.5 mg/kg, sc) 30 min 
later. Ten minutes after the second injection, rats were placed in 
the PPI boxes and tested.
2.3.2. Experiment 2: Effects of repeated olanzapine (2.0 mg/
kg, sc), risperidone (1.0 mg/kg, sc) and quetiapine (10.0 mg/
kg, sc) treatment on repeated PCP (1.5 mg/kg, sc)-induced PPI 
disruption
Experiment 2 tested the potential reversal effect of repeated 
olanzapine (2.0 mg/kg, sc), risperidone (1.0 mg/kg, sc) and que-
tiapine (10.0 mg/kg, sc) treatment on repeated PCP (1.5 mg/
kg, sc)-induced PPI disruption. The basic procedure was iden-
tical to that of Experiment 1. Sixty rats were assigned to five 
groups based on the averaged% PPI on the saline day (n = 12/
group): VEH (sterile water, sc) + VEH (saline, sc), VEH + PCP, 
OLZ + PCP, RIS + PCP, and QUE + PCP. They were subjected to 6 
consecutive drug tests.
2.4. Experiment 3: Effects of repeated clozapine (5.0 and 
10 mg/kg, sc) treatment on repeated PCP (1.5 mg/kg, sc)-in-
duced PPI disruption
Experiment 3 was conducted to examine a possible dose-depen-
dent attenuation effect of repeated clozapine treatment on re-
peated PCP (1.5 mg/kg, sc)-induced PPI disruption. The basic 
procedure was identical to that of Experiment 1. Forty-eight rats 
were assigned to 4 groups based on the averaged% PPI on the sa-
line day (n = 12/group): VEH (sterile water, sc) + VEH (saline, 
sc), VEH + PCP, CLZ-5.0 + PCP, and CLZ-10.0 + PCP. They were 
subjected to 6 consecutive drug tests.
2.5. Statistical analysis
Percent PPI data for the 6 drug days were presented separately 
for three prepulse intensities (e.g. 73, 76 and 82 dB). The magni-
tude of the acoustic startle reflex (ASR) was calculated as the av-
erage response on the PULSE ALONE trials, excluding the first 
and last block of 4 PULSE ALONE trials. The general activity was 
calculated as the average response on the NOSTIM trials. Per-
cent PPI, ASR and activity data from the drug test period were 
first analyzed using repeated measures ANOVAs with drug treat-
ment group as a between-subjects factor and test day (i.e. 6) as 
a within-subjects factor. For PPI data, another within-subjects 
factor (i.e. 3 prepulse levels) was also included in the analysis. 
When a significant test day × group interaction was found, the 
time course of antipsychotic treatment effect on PCP-induced 
PPI deficit was re-analyzed using repeated measures ANOVA 
(i.e. 3 prepulse levels × 6 days) involving only one antipsychotic 
group (e.g. RIS + PCP). One-way analyses of variance (ANOVA) 
followed by post hoc LSD tests were used to identify between-
group differences at specific prepulse level on specific days. For 
all analyses, P < 0.05 was considered statistically significant.
3. Results
3.1. Experiment 1: Effects of repeated haloperidol (0.05 mg/
kg, sc) and clozapine (10 mg/kg, sc) treatment on repeated 
PCP (1.5 mg/kg, sc)-induced PPI disruption
3.1.1. PPI
As expected, there was no group difference on the averaged per-
cent PPI on the saline day (F(3, 44) = 0.566, P = 0.641). Analysis of 
PPI data from the 6 drug test days revealed a main effect of group 
(F(3, 44) = 18.583, P < 0.001), prepulse level (F(2, 88) = 363.307, 
P < 0.001) and test day (F(5, 220) = 4.550, P = 0.001), and a sig-
nificant prepulse level × group interaction (F(6, 88) = 3.805, 
P = 0.002). This analysis suggests that the PCP effect and anti-
psychotic treatment effect were stable across the 6 test days (no 
test day × group interaction) but varied at different prepulse lev-
els. LSD post hoc tests revealed that the VEH + PCP group dif-
fered significantly from the VEH + VEH group (P < 0.001), in-
dicating a strong PPI disruptive effect of PCP. Importantly, the 
CLZ + PCP group differed significantly from the VEH + PCP 
(P < 0.001), indicating an attenuation effect of repeated CLZ 
on PCP-induced PPI disruption. CLZ at this dose (10.0 mg/kg) 
did not completely normalize PCP-induced PPI deficit as the 
CLZ + PCP group still differed significantly from the VEH + VEH 
group (P = 0.009). Unlike CLZ, HAL did not improve PCP-in-
duced PPI deficits, as evidenced by the lack of significant differ-
ence between the HAL + PCP and VEH + PCP group (P = 0.617).
To examine significant group difference at each prepulse 
level on each drug test day, one-way ANOVAs followed by post 
hoc LSD tests were used. At the 73 dB prepulse intensity level 
(Figure 1A), the VEH + PCP group had significantly lower PPI 
than the VEH + VEH group on all test days (all Ps < 0.030). 
The CLZ + PCP group had significantly higher PPI than the 
VEH + PCP group on days 1 (P = 0.024) and 5 (P = 0.022), 
whereas the HAL + PCP group did not show such an attenuation 
effect (all Ps > 0.130). At the 76 dB prepulse intensity level (Fig-
ure 1B), the VEH + PCP and HAL + PCP groups had significantly 
lower PPI than the VEH + VEH group on all drug test days (all 
Ps < 0.002). CLZ significantly reduced PCP-induced disruption 
on all days (Ps < 0.030) except on day 2 (P = 0.069), whereas HAL 
had no effect (all Ps > 0.136).
At the 82 dB prepulse intensity level (Figure 1C), the 
VEH + PCP and HAL + PCP groups had significantly lower PPI 
than the VEH + VEH group on all drug test days (all Ps < 0.002). 
Once again, CLZ significantly reduced PCP-induced disruption 
on all days (Ps < 0.035) except on day 2 (P = 0.201), whereas HAL 
had no effect (all Ps > 0.189).
Overall, our data suggests that PCP at the tested dose pro-
duced a persistent disruption of sensorimotor gating as mea-
sured in the PPI paradigm, especially at the 76 and 82 dB pre-
pulse levels. Pretreatment of CLZ, but not HAL, attenuated 
PCP-induced PPI deficits and this attenuation started early and 
was maintained throughout the testing period.
3.1.2. Acoustic startle response (ASR)
The startle magnitudes over the six drug test days were sub-
stantially higher in rats that were treated with VEH + PCP or 
HAL + PCP. Pretreatment of CLZ completely normalized this 
effect of PCP (Figure 2A). Repeated measures ANOVA shows a 
main effect of group (F(3, 44) = 10.394, P < 0.001) and a signifi-
cant interaction between group and test day (F(15, 220) = 2.692, 
P = 0.001). Post hoc tests show that the VEH + VEH and 
CLZ + PCP groups did not differ from each other, but did dif-
fer significantly from the VEH + PCP and HAL + PCP groups 
(Ps = 0.001). Individual one-way ANOVAs followed by LSD post 
hoc tests on each test day indicated that both the VEH + VEH 
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and CLZ + PCP groups differed significantly from the VEH + PCP 
and HAL + PCP groups on every test day (all Ps < 0.022). There-
fore, similar to their effects on PPI, CLZ is categorically different 
from HAL on PCP-induced increase of startle response.
3.1.3. General activity
The motor activities recorded during the NOSTIM trials were 
substantially higher in rats that were treated with VEH + PCP or 
HAL + PCP. Again, pretreatment of CLZ completely normalized 
this effect of PCP (Figure 2B). Interestingly, pretreatment of HAL 
also reduced this effect of PCP, especially towards the end of 
drug testing sessions. Repeated measures ANOVA shows a main 
effect of group (F(3, 44) = 19.611, P < 0.001), a main effect of test 
day (F(5, 220) = 3.931, P = 0.002), and a significant interaction 
between group and test day (F(15, 220) = 3.358, P < 0.001). In-
dividual tests on each test day also indicate that the VEH + PCP 
group differed significantly from the VEH + VEH and CLZ + PCP 
group on every test day (all Ps < 0.032). The HAL + PCP group 
differed significantly from the VEH + VEH group only on the 
first 5 test days (all Ps < 0.013), but not on the last day (P = 0.142) 
when it also differed significantly from the VEH + PCP group 
(P = 0.003).
3.2. Experiment 2: Effects of repeated olanzapine (2.0 mg/
kg, sc), risperidone (1.0 mg/kg, sc) and quetiapine (10.0 mg/
kg, sc) treatment on repeated PCP (1.5 mg/kg, sc)-induced 
PPI disruption
3.2.1. PPI
Analysis of PPI data from the 6 drug test days revealed a main 
effect of group (F(4, 55) = 21.178, P < 0.001), prepulse level 
(F(2, 110) = 734.820, P < 0.001) and test day (F(5, 275) = 10.548, 
P < 0.001). There was also a significant day × group interaction 
(F(20, 275) = 1.851, P = 0.016), a significant prepulse level × group 
interaction (F(8, 110) = 7.316, P < 0.001), and a significant pre-
pulse level × day interaction (F(10, 550) = 2.778, P = 0.002). LSD 
Figure 1. Effects of repeated haloperidol (0.05 mg/kg, sc) or clozapine (10.0 mg/kg, sc) treatment on the repeated PCP (1.5 mg/kg, sc)-induced disrup-
tion of PPI at the 73 dB (A), 76 dB (B) and 82 dB (C) prepulse levels. * P < 0.05 in comparison to the VEH + VEH group; # P < 0.05 in comparison to the 
VEH + PCP group.
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post hoc tests revealed that the VEH + PCP group differed sig-
nificantly from the VEH + VEH group (P < 0.001), indicating a 
strong PPI disruptive effect of PCP. Importantly, the RIS + PCP 
and QUE + PCP group differed significantly from the VEH + PCP 
(P = 0.005 and 0.001, respectively), indicating an attenuation ef-
fect of repeated RIS and QUE on PCP-induced PPI disruption. 
Both RIS and QUE at the tested doses did not completely normal-
ize PCP-induced PPI deficit as both groups still differed signifi-
cantly from the VEH + VEH group (Ps < 0.001). Interestingly, the 
OLZ + PCP group did not differ significantly from the VEH + PCP 
group (P = 0.698), suggesting a lack of effect with repeated 
OLZ treatment. Repeated measures ANOVA involving only the 
RIS + PCP group showed a main effect of test day (F(5, 55) = 9.159, 
P < 0.001), a main effect of prepulse level (F(2, 22) = 186.463, 
P < 0.001), and a significant test day × prepulse level interaction 
(F(10, 110) = 2.030, P = 0.037), suggesting that with repeated treat-
ment, risperidone enhanced its effects on PCP-induced PPI dis-
ruption. For QUE + PCP group, the main effect of test day was not 
significant (F(5, 55) = 1.848, P = 0.119), suggesting that the que-
tiapine’s effect remained stable across the test days.
At the 73 dB prepulse intensity level (Figure 3A), one-
way ANOVA followed by the post hoc tests showed that 
the VEH + PCP group had significantly lower PPI than the 
VEH + VEH group on days 1, 2, 4 and 5 test days (all Ps < 0.010). 
The QUE + PCP group had significantly higher PPI than the 
VEH + PCP group only on one test day (day 2, P = 0.006).
At the 76 dB prepulse intensity level (Figure 3B), the 
VEH + PCP and OLZ + PCP groups had significantly lower PPI 
than the VEH + VEH group on all drug test days (all Ps < 0.010). 
RIS significantly reduced PCP-induced disruption on days 4 and 
6 (Ps < 0.002). QUE significantly reduced PCP-induced disrup-
tion on days 2, 4, 5 and 6 (all Ps < 0.042).
At the 82 dB prepulse intensity level (Figure 3C), the 
VEH + PCP and OLZ + PCP groups had significantly lower PPI 
than the VEH + VEH group on all drug test days (all Ps < 0.002) 
except on day 3 (Ps > 0.073). Once again, RIS significantly re-
duced PCP-induced disruption on all test days (Ps < 0.025) ex-
cept on day 1 (P = 0.121). QUE significantly reduced PCP-induced 
disruption on days 4, 5 and 6 (all Ps < 0.012).
These results confirmed that PCP at the tested dose is capa-
ble of producing persistent PPI deficit. Pretreatment of RIS and 
QUE, but not OLZ, attenuated PCP-induced PPI deficits. It ap-
pears that the attenuation effect of RIS tended to increase while 
that of QUE maintained throughout the treatment period.
3.2.2. Acoustic startle response (ASR)
The startle magnitudes over the 6 drug test days were substan-
tially higher in rats treated with VEH + PCP, and to a lesser ex-
tent, OLZ + PCP. Pretreatment of RIS and QUE, and, to a lesser 
extent, OLZ, reduced the startle-enhancing effect of PCP (Fig-
ure 4A). Repeated measures ANOVA shows a main effect of 
group (F(4, 55) = 8.733, P < 0.001), a main effect of test day (F(5, 
275) = 6.111, P < 0.001), and a significant group × test day inter-
action (F(20, 275) = 2.408, P = 0.001). LSD post hoc tests show 
that the VEH + PCP group differed significantly from all other 
groups (all Ps < 0.024). Only the RIS + PCP group did not dif-
fer significantly from the VEH + VEH group (P = 0.104), suggest-
ing that pretreatment of RIS normalized this effect of PCP. All 
other groups had significantly higher startle reactivity than the 
VEH + VEH group (Ps < 0.010). Analysis on each test day indi-
cated that in comparison to the VEH + PCP group, the RIS + PCP 
and QUE + PCP groups had significantly lower startle magni-
tude on all 6 test days (all Ps < 0.016) and the OLZ + PCP group 
on days 1, 2 and 4 (Ps < 0.034). Therefore, all three atypical an-
Figure 2. Effects of repeated haloperidol (0.05 mg/kg, sc) or clozapine (10.0 mg/kg, sc) treatment on the repeated PCP (1.5 mg/kg, sc)-induced increase 
in the acoustic startle response (ASR) (A) and general activity (B). * P < 0.05 in comparison to the VEH + VEH group; # P < 0.05 in comparison to the 
VEH + PCP group.
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tipsychotics were effective in reducing PCP-induced increase 
on startle response, but RIS and QUE at the tested doses had a 
more robust and consistent effect.
3.2.3. General activity
The motor activities recorded during the NOSTIM trials were 
substantially higher in rats that were treated with VEH + PCP. 
Again, pretreatment of RIS, QUE and OLZ reduced this effect of 
PCP (Figure 4B). Repeated measures ANOVA shows a main ef-
fect of group (F(4, 55) = 9.415, P < 0.001), a main effect of test day 
(F(5, 275) = 10.757, P < 0.001), and a significant interaction be-
tween group and test day (F(20, 275) = 6.179, P < 0.001). LSD post 
hoc tests showed that the VEH + PCP differed significantly from 
the VEH + VEH, RIS + PCP and QUE + PCP groups (Ps < 0.001), 
but not from the OLZ + PCP group (P = 0.09). Individual tests 
on each test day indicate that in comparison to the VEH + PCP 
group, the three antipsychotic treated groups (i.e. RIS + PCP, 
QUE + PCP and OLZ + PCP) had significantly lowered mo-
tor activity on days 4, 5 and 6 (all Ps < 0.004). In addition, the 
OLZ + PCP group had significantly enhanced motor activity on 
day 1 (P = 0.006), whereas the RIS + PCP and QUE + PCP had 
significantly lowered motor activity on day 2 (Ps < 0.010). Like 
their effects on PCP-induced increase on startle response, re-
peated atypical antipsychotic treatment was able to reducing the 
psychomotor stimulating effect of PCP.
3.3. Experiment 3: Effects of repeated clozapine (5.0 and 
10 mg/kg, sc) treatment on repeated PCP (1.5 mg/kg, sc)-in-
duced PPI disruption
3.3.1. PPI
Analysis of PPI data from the 6 drug test days revealed a main 
effect of group (F(3, 44) = 7.892, P < 0.001), prepulse level 
(F(2, 88) = 608.366, P < 0.001) and test day (F(5, 220) = 2.675, 
P = 0.023). LSD post hoc tests revealed that the VEH + PCP group 
differed significantly from the VEH + VEH group (P < 0.001), in-
Figure 3. Effects of repeated olanzapine (2.0 mg/kg, sc), risperidone (1.0 mg/kg, sc), or quetiapine (10.0 mg/kg, sc) treatment on the repeated PCP 
(1.5 mg/kg, sc)-induced disruption of PPI at the 73 dB (A), 76 dB (B) and 82 dB (C) prepulse levels. * P < 0.05 in comparison to the VEH + VEH group; # 
P < 0.05 in comparison to the VEH + PCP group.
Time course of the attenuation effect of repeated antipsychotic treatment   565
dicating a strong PPI disruptive effect of PCP. Importantly, both 
CLZ groups differed significantly from the VEH + PCP (P = 0.021 
for CLZ 5.0 and P = 0.008 for CLZ 10.0), indicating an attenu-
ation effect of repeated CLZ on PCP-induced PPI disruption, 
which did not change over time (no significant test day × group 
interaction). CLZ at 5 and 10 mg/kg did not completely normal-
ize PCP-induced PPI deficit as both groups still differed signif-
icantly from the VEH + VEH group (P = 0.019 for CLZ 5.0 and 
P = 0.045 for CLZ 10.0).
At the 73 dB prepulse intensity level (Figure 5A), one-way 
ANOVA followed by the post hoc tests showed that the VEH + PCP 
group had significantly lower PPI than the VEH + VEH group on 
days 1, 3 and 4 (all Ps < 0.003). In comparison to the VEH + PCP 
group, the CLZ-5.0 + PCP group had significantly higher PPI on 
days 1 (P = 0.005) and 3 (P = 0.006), and the CLZ-10.0 + PCP group 
had significantly higher PPI on days 1 (P = 0.045).
At the 76 dB prepulse intensity level (Figure 5B), the 
VEH + PCP group had significantly lower PPI than the 
VEH + VEH group on all drug test days (all Ps < 0.002) except 
on the last day (P = 0.111). The CLZ-5.0 + PCP group had lower 
PPI on day 1 (P = 0.027), day 2 (P = 0.003), and day 4 (P = 0.036), 
while the CLZ-10.0 + PCP group had lower PPI on days 1 and 5 
(Ps = 0.045). Both CLZ groups did not differ significantly from 
the VEH + PCP group on any of the test days (all Ps > 0.05).
At the 82 dB prepulse intensity level (Figure 5C), the 
VEH + PCP group had significantly lower PPI than the 
VEH + VEH group on all drug test days (all Ps < 0.009) except 
on day 2 (P = 0.070). In comparison to the VEH + PCP group, 
the CLZ-5.0 + PCP group had significantly higher PPI on days 1, 
3 and 6 (all Ps < 0.040), and the CLZ-10.0 + PCP group had sig-
nificantly higher PPI on the last four days (all Ps < 0.041), in-
dicating a clear attenuation effect of repeated CLZ on PCP-in-
duced PPI disruption.
These results confirmed that pretreatment of CLZ at both 
5.0 mg/kg and 10.0 mg/kg were equally effective in attenuat-
ing PCP-induced PPI disruption. This attenuation effect was 
most apparent at the 82 dB prepulse level and was maintained 
throughout the testing period.
3.3.2. Acoustic startle response (ASR)
The startle magnitudes over the six drug test days were substan-
tially higher in rats from the VEH + PCP group. Pretreatment 
of CLZ at both doses completely normalized this effect of PCP 
(Figure 6A). Repeated measures ANOVA shows a main effect 
of group (F(3, 44) = 16.721, P < 0.001). Post hoc tests show that 
the VEH + PCP group differed significantly from all other three 
groups (all Ps < 0.001), which did not differ from each other (all 
Ps > 0.333). Individual one-way ANOVAs followed by LSD post 
hoc tests revealed that the VEH + PCP group differed signifi-
cantly from all other groups on every test day (all Ps < 0.007).
3.3.3. General activity
The motor activities recorded during the NOSTIM trials were sub-
stantially higher in rats that were treated with VEH + PCP. Again, 
pretreatment of CLZ at both doses completely normalized this ef-
fect of PCP (Figure 6B). Repeated measures ANOVA shows a main 
effect of group (F(3, 44) = 8.180, P < 0.001), a main effect of test 
day (F(5, 220) = 2.518, P = 0.031), and a significant interaction be-
tween group and test day (F(15, 220) = 5.098, P < 0.001). Post hoc 
tests show that the VEH + PCP group differed significantly from 
all other three groups (all Ps < 0.001), which did not differ from 
each other (all Ps > 0.840). Individual tests on each test day also 
indicate that the VEH + PCP group differed significantly from the 
VEH + VEH group on every test day (all Ps < 0.004) except on day 
1 (P = 0.077). Both CLZ groups also differed significantly from the 
VEH + PCP group on days 1 to 6 (all Ps < 0.002).
Figure 4. Effects of repeated olanzapine (2.0 mg/kg, sc), risperidone (1.0 mg/kg, sc), or quetiapine (10.0 mg/kg, sc) treatment on the repeated PCP 
(1.5 mg/kg, sc)-induced increase in the acoustic startle response (ASR) (A) and general activity (B). * P < 0.05 in comparison to the VEH + VEH group; # 
P < 0.05 in comparison to the VEH + PCP group.
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4. Discussion
As hypothesized, the present study shows that repeated treat-
ment of three atypical antipsychotic drugs, clozapine, risperi-
done and quetiapine reduced the PPI deficit induced by repeated 
administration of PCP. In contrast, repeated treatment of halo-
peridol and olanzapine was ineffective. The PPI effects of these 
drugs were dissociable from their effects on startle response and 
general activity. For example, olanzapine and haloperidol had no 
effect on PCP-induced PPI deficit, but were able to reduce PCP-
induced increase in startle response and general motor activ-
ity. Finally, the magnitude of the attenuation effect of repeated 
clozapine, risperidone and quetiapine on PCP-induced PPI dis-
ruption was dependent on the prepulse level. It was most stable 
and conspicuous at a higher prepulse level (e.g. 82 dB) than at a 
lower level (e.g. 73 dB).
It has been suggested that the acute PCP-PPI model is able to 
differentiate atypical from typical antipsychotics based on their 
acute effects in this model (Geyer and Ellenbroek, 2003). Typi-
cal antipsychotics such as haloperidol are ineffective in reduc-
ing the effects of PCP (see a comprehensive review, Geyer et al., 
2001). Our current result is consistent with this general observa-
tion, suggesting that the lack of haloperidol effect is due to its 
intrinsic inability to antagonize PCP in this model. Studies on 
atypical antipsychotics so far have yielded inconsistent results 
(Geyer et al., 2001; Swerdlow et al., 1996). The majority of stud-
ies show that clozapine (Bakshi et al., 1994), olanzapine (Bakshi 
and Geyer, 1995; Wiley and Kennedy, 2002), risperidone (Pouzet 
et al., 2002b) and quetiapine (Swerdlow et al., 1996) reduce PCP-
induced PPI disruption. Others, including our own, have failed 
to find such an ameliorating effect with clozapine (Pouzet et al., 
2002a; Schwabe et al., 2005; Sun et al., 2010; Wiley and Kennedy, 
2002), olanzapine (Fejgin et al., 2007), and risperidone (Swerd-
low et al., 1996). These inconsistent findings are likely due to 
methodological differences such as PPI testing procedure, test-
ing apparatus, pulse and prepulse parameters, drug doses, ad-
Figure 5. Effects of repeated clozapine (5.0 and 10.0 mg/kg, sc) treatment on the repeated PCP (1.5 mg/kg, sc)-induced disruption of PPI at the 73 dB 
(A), 76 dB (B) and 82 dB (C) prepulse levels. * P < 0.05 in comparison to the VEH + VEH group; # P < 0.05 in comparison to the VEH + PCP group.
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ministration route, rat strains, etc. as opposed to a total lack of 
effects. In this regard, the PCP dose may be an important fac-
tor. For instance, Sun et al. (2010) failed to observe any reversal 
effect of clozapine (10 mg/kg) against the PPI deficit induced by 
PCP (2.0 mg/kg). However, the same dose of clozapine reduced 
the effect of PCP at 1.5 mg/kg in the present study. Similarly, 
Swerdlow et al. (1996) found that quetiapine (5.0–7.5 mg/kg) re-
versed the effect of a lower dose of PCP (1.25 mg/kg). When PCP 
at 1.5 mg/kg was used, acute quetiapine (10 mg/kg) was unable 
to significantly reverse its disruption (Figure 3). The dose of anti-
psychotic drugs is certainly another important factor. For exam-
ple, our failure to observe a reversal effect with olanzapine may 
be due to the fact that a lower dose of olanzapine (2.0 mg/kg) 
was used. Bakshi and Geyer (1995) showed that olanzapine’s ef-
fect in the PCP–PPI model was dose-dependent and it only be-
came effective when the doses reached 5.0 mg/kg. Using the 
same procedure as described in this study, we recently confirmed 
the lack of effect of repeated olanzapine treatment at 1.0 and 
2.0 mg/kg on PCP (1.5 mg/kg)-induced PPI disruption (unpub-
lished observation).
In contrast to many studies on acute effects of antipsychotic 
drugs in deficient PPI models, there are only a handful of stud-
ies that examined the time course of repeated treatment effect 
of antipsychotics on PPI deficits induced by NMDA antago-
nists. They all focused on typical antipsychotic haloperidol and 
showed that chronic treatment with this drug (1 mg/kg/day) via 
osmotic minipumps or drinking water attenuated but not com-
pletely normalized PCP-induced disruption of PPI (Martinez et 
al., 2000; Pietraszek and Ossowska, 1998). They also reported 
that short-term treatment (4–7 days) was ineffective. In light of 
these findings, the lack of haloperidol effect in the present study 
may be due to inadequate treatment duration or mode of drug 
delivery, thus longer treatment and continuous dopamine D2 oc-
cupancy achieved via osmotic minipump delivery (Kapur et al., 
2003) may have produced statistically significant effects. This 
possibility needs to be examined in future study.
The present study revealed that repeated treatment with 
clozapine, risperidone and quetiapine maintained or progres-
sively enhanced their antagonistic effects against PCP-induced 
PPI deficit. To the best of our knowledge, this is the first report 
that shows a time-dependent effect of atypicals in the PCP–PPI 
model. In a related work, Feifel et al. (2007) found a similar effect 
with risperidone and clozapine in the vasopressin deficient Brat-
tleboro (BRAT) rats (a natural model for sensorimotor deficits). 
They reported that 16-day treatment with risperidone (1.0 mg/
kg) and clozapine (7.5 mg/kg), but not haloperidol (0.5 mg/kg), 
increased PPI to a greater extent than only one day treatment 
with these antipsychotic drugs. The importance of our finding is 
that the overall pattern of change induced by repeated clozapine, 
risperidone and quetiapine treatment resembles what we have 
found in the conditioned avoidance response model and the PCP 
hyperlocomotion model (Li et al., 2007, 2010; Mead and Li, 2010; 
Sun et al., 2009). It suggests that there may be a commonality 
among these models in detecting antipsychotic-like activity. It 
also indicates that, similar to the repeated conditioned avoid-
ance response model and the PCP hyperlocomotion model, the 
repeated PCP–PPI model is also capable of capturing the time 
course of antipsychotic action, at least for the three atypicals (i.e. 
clozapine, risperidone and quetiapine). One surprising finding 
is that olanzapine 2.0 mg/kg failed to show any effect, although 
this dose of olanzapine shows a robust enhanced inhibition on 
conditioned avoidance response and on PCP-induced increase in 
locomotor activity with repeated treatment. From this perspec-
tive, the conditioned avoidance response and PCP hyperloco-
motion models may be more sensitive to the intrinsic “antipsy-
chotic activity” than the repeated PCP–PPI model. Even within 
Figure 6. Effects of repeated clozapine (5.0 and 10.0 mg/kg, sc) treatment on the repeated PCP (1.5 mg/kg, sc)-induced increase in the acoustic star-
tle response (ASR) (A) and general activity (B). * P < 0.05 in comparison to the VEH + VEH group; # P < 0.05 in comparison to the VEH + PCP group.
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the PPI model, among the three behavioral measures typically 
reported by many studies (i.e. PPI, startle reactivity and gen-
eral motor activity), PPI seems least sensitive and consistent to 
a treatment effect of an antipsychotic drug. For instance, in Ex-
periment 1, repeated haloperidol treatment significantly reduced 
PCP-induced increase on motor activity on days 5 and 6, but it 
did not reduce PCP-induced PPI disruption at any prepulse level 
on any day. In Experiment 2, repeated olanzapine treatment re-
duced PCP-induced increase in startle response and motor ac-
tivity, had little effect on PCP-induced PPI disruption. Similarly, 
in both Experiments 1 and 3, repeated clozapine consistently re-
duced PCP-induced increase in startle reactivity and motor ac-
tivity throughout the testing period and showed a rather good 
consistence between the two experiments (Figure 2 & Figure 6), 
however, its effect on PCP-induced PPI disruption was not stabi-
lized until the 2–3 days of testing and it showed large variations 
at the different prepulse levels and between the experiments. 
For example, clozapine’s attenuation effect on PPI at the 76 dB 
level found in Experiment 1 was not replicated in Experiment 3. 
It appears that the measurements of startle reactivity and gen-
eral motor activity detect a common treatment effect of antipsy-
chotics better than PPI. One difficulty in detecting a robust and 
shared effect on PPI may be due to the complex psychological 
and neurobiological processes involved in PCP-induced PPI defi-
cit (Swerdlow et al., 2008).
Mechanisms underlying the PCP-induced PPI deficit and its 
attenuation by repeated treatment with clozapine, risperidone 
and quetiapine are not known. PCP is a drug of abuse that has a 
wide range of psychotomimetic effects in humans (Jentsch and 
Roth, 1999). Besides blocking NMDA receptor channels, PCP 
also enhances serotonergic and dopaminergic neurotransmission 
in the nucleus accumbens and prefrontal cortex (Abekawa et al., 
2007; Maurel-Remy et al., 1995; Millan et al., 1999). One interest-
ing possibility is that PCP may disrupt PPI by stimulating 5-HT2A 
receptors, and antipsychotics may reverse this effect by down-reg-
ulating 5-HT2A receptors and concomitantly decreasing PCP-in-
duced dopamine and 5-HT increases in the prefrontal cortex. This 
hypothesis is supported by the findings that the ability of antipsy-
chotics to restore PPI in PCP-treated rats correlated significantly 
with their affinity for 5-HT2A receptors (Yamada et al., 1999) and 
repeated administration of clozapine causes a down-regulation 
of 5-HT2A receptors in the prefrontal cortex (Doat-Meyerhoefer 
et al., 2005). Another possibility is that antipsychotics achieve 
their efficacy through action on α1-adrenergic receptors (Bakshi 
and Geyer, 1997). All antipsychotic drugs tested here have an ap-
preciable antagonistic action on α1-adrenergic receptors (Miya-
moto et al., 2005). Bakshi and Geyer (1997) also reported that the 
α1-adrenergic antagonist prazosin can reduce the disruptive effect 
of PCP on PPI. Therefore, it is possible that clozapine, risperidone 
and quetiapine may reduce the effects of PCP by blocking α1-
adrenergic receptors. If future work demonstrates that repeated 
haloperidol and olanzapine could also reverse the disruptive effect 
of PCP on PPI, it would provide strong support for this hypoth-
esis. The outcome of this line of research may shed light on the 
pathophysiology of schizophrenia and the molecular mechanisms 
responsible for antipsychotic action.
We should point out several limitations with the current re-
port. First, in this study, we only used one or two doses of these 
drugs, and thus the effect (or no-effects) may be related to the 
dose used in this study. Second, we merely tested their effects 
on PCP-induced PPI deficits, but there are other transmitter sys-
tems (e.g., dopamine, serotonin) that are also involved in defi-
cient sensorimotor gating. Using these transmitter systems to 
induce deficient PPI may have resulted in different outcome. 
Third, we did not test how antipsychotics by themselves would 
affect PPI, thus, it is difficult to determine whether the attenua-
tion effect was due to their specific effects on PCP or their intrin-
sic potentiating effect on normal level of PPI. Finally, the base-
line levels of PPI, experimental parameters, and testing schedule 
are important determinants of drug effects (Barrett et al., 2008; 
Geyer et al., 2001). Thus the generalization of the drug effects 
found in this report could not be made until they have been rig-
orously tested under a broad range of conditions.
Understanding how repeated antipsychotic treatment affects 
PPI deficits induced by psychotomimetic drugs is important for 
identification of the mechanisms underlying the clinically rel-
evant action of antipsychotics. The present study provides an-
other animal preparation for studying antipsychotic drugs. To-
gether with the conditioned avoidance response model and the 
PCP-induced hyperlocomotion model based on repeated treat-
ment regimens (Li et al., 2007, 2010; Sun et al., 2009), the re-
peated PCP–PPI model could help enhance our understanding 
of the neurobiological and behavioral mechanisms of antipsy-
chotic action which in turn, may help understand the neurobio-
logical and behavioral mechanisms of psychosis.
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